Context Therapeutics Launches Phase 1 Trial of CT-95
Context Therapeutics Inc. (Nasdaq: CNTX), a leading biopharmaceutical company focused on innovative T cell engaging therapies for solid tumors, has taken a significant step by dosing the first patient in the Phase 1 clinical trial of its novel bispecific antibody, CT-95. This pioneering clinical study is expected to shed light on the potential effectiveness of CT-95 in targeting mesothelin-expressing cancers.
Understanding CT-95
CT-95 is designed as a mesothelin x CD3 T cell engaging bispecific antibody, specifically aimed at patients with advanced cancers that express mesothelin. This protein is notable for its presence in a wide array of tumors, including pancreatic, ovarian, and mesothelioma cancers, while being minimally expressed in healthy tissues. The targeted approach of CT-95 presents a promising route in immunotherapy, with hopes of enhancing treatment outcomes for patients battling these aggressive forms of cancer.
Significance of the Trial
The initiation of the CT-95 trial marks Context Therapeutics' second clinical endeavor, indicative of the company’s growth and commitment to advancing cutting-edge therapies. The trial aims to explore the safety and effectiveness of CT-95 as it progresses through both dose escalation and expansion phases. As part of the study framework, up to 30 patients will be enrolled, enabling researchers to monitor pharmacokinetics and overall response rates to the treatment.
CEO Martin Lehr's Insights
“The dosing of our first patient in the CT-95 Phase 1 clinical trial symbolizes a crucial advancement in our mission to create next-generation immunotherapies for solid tumors,” stated Martin Lehr, the Chief Executive Officer of Context Therapeutics. The ability to bring both CT-95 and another candidate, CTIM-76, into initial patient dosing phases demonstrates Context’s strong clinical pipeline and leadership in the bispecific antibody space.
Clinical Objectives of CT-95
In the preliminary phase of the trial, researchers will assess the treatment's safety profile, tolerability levels, and its capability to engage and activate T cells to combat tumor cells effectively. The clinical objectives focus on the overall response rate, duration of response, and the disease control rate among participants. This comprehensive evaluation is vital in determining the potential for CT-95 to become a standard therapeutic option for patients facing advanced cancers associated with mesothelin presence.
Challenges in MSLN-targeted Therapies
Developing therapies that target mesothelin, like CT-95, has its challenges. A notable complication is the existence of shed MSLN fragments within both blood circulation and the tumor microenvironment. These fragments can act as decoys, diminishing the efficacy of targeting antibodies. However, CT-95 is engineered to maintain strong binding affinity to membrane-bound MSLN, potentially mitigating the impact of these shed proteins.
Continuing Commitment to Innovation
Context Therapeutics is not only committed to CT-95 but is building an extensive pipeline of bispecific antibodies, including CTIM-76 and CT-202, aimed at various cancer types. With a focus on advancing T cell engaging therapies, Context is positioned at the forefront of innovation in cancer treatment.
Contact Information
For those seeking further information regarding Context Therapeutics or investor relations inquiries, please reach out to:
Jennifer Minai-Azary
Chief Financial Officer
Context Therapeutics Inc.
IR@contexttherapeutics.com
Frequently Asked Questions
What is CT-95?
CT-95 is a bispecific antibody targeting mesothelin-expressing cancers, designed to engage T cells for an enhanced immune response against tumors.
Who is conducting the Phase 1 trial for CT-95?
The trial is being conducted by Context Therapeutics Inc., a biopharmaceutical company dedicated to developing advanced therapies for solid tumors.
What is the primary focus of the Phase 1 trial?
The primary focus is to evaluate the safety, tolerability, and efficacy of CT-95 in patients with mesothelin-expressing advanced solid tumors.
Why is mesothelin important in cancer therapy?
Mesothelin is overexpressed in around 30% of all cancers, making it a crucial target for therapies aimed at treating aggressive tumors.
How can I learn more about Context Therapeutics?
For more information, visit their official website at contexttherapeutics.com.
